Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis

医学 特应性皮炎 湿疹面积及严重程度指数 内科学 相对风险 安慰剂 置信区间 随机对照试验 胃肠病学 不利影响 免疫学 病理 替代医学
作者
Chenyang Li,Xun Sun,Kun Zhao,Fanxiang Meng,Dan Li,Zhenzhen Mu,Xiuping Han
出处
期刊:Dermatology [S. Karger AG]
卷期号:238 (4): 725-735 被引量:25
标识
DOI:10.1159/000518541
摘要

<b><i>Background:</i></b> Current therapeutic options for atopic dermatitis (AD) are limited. Janus kinase (JAK) inhibitors may be viable alternatives. <b><i>Objectives:</i></b> To assess the efficacy and safety of JAK inhibitors for AD treatment. <b><i>Methods:</i></b> We searched PubMed, Embase, the Cochrane Controlled Register of Trials, Web of Science, Global Resource of Eczema Trials database, and ClinicalTrials.gov from inception to September 1, 2020. Randomized clinical trials (RCTs) comparing JAK inhibitors with placebo/vehicle treatment for AD patients were included. The primary study outcomes included (1) the change (%) from the Eczema Area and Severity Index (EASI) baseline expressed as weighted mean difference (WMD) and 95% confidence interval (95% CI), and (2) the Investigator’s Global Assessment (IGA) response and safety outcomes expressed as relative risk (RR) and 95% CI. <b><i>Results:</i></b> We included 14 RCTs published in 13 studies (3,822 patients). Treatment with JAK inhibitors significantly improved IGA response (RR 2.83, 95% CI 2.25–3.56, <i>p</i> &#x3c; 0.001) and EASI score (WMD –28.82, 95% CI –34.48 to −23.16, <i>p</i> &#x3c; 0.001). JAK inhibitor treatment achieved the largest improvement in both IGA response (RR 3.59, 95% CI 2.66–4.84, <i>p</i> &#x3c; 0.001) and EASI score (WMD –42.00, 95% CI –48.64 to −35.36, <i>p</i> &#x3c; 0.001) by week 4 of treatment. Topical JAK inhibitors were significantly more efficacious than oral inhibitors. Upadacitinib treatment for 4 weeks was most effective in reducing EASI score (WMD –53.92, 95% CI –69.26 to −38.58, <i>p</i> &#x3c; 0.001), while abrocitinib for 4 weeks led to the most effective IGA response (RR 5.47, 95% CI 2.74–10.93, <i>p</i> &#x3c; 0.001). There was no difference in the frequency of adverse events (AEs) leading to discontinuation; however, JAK inhibitors use, especially abrocitinib, led to a higher incidence of treatment-emergent AEs (RR 1.25, 95% CI 1.10–1.42, <i>p</i> = 0.001). <b><i>Conclusion:</i></b> Our results imply that JAK inhibitors are an effective and safe AD treatment. Nevertheless, further trials with longer duration and head-to-head comparisons of different JAK inhibitors are needed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Maestro_S应助Hui_2023采纳,获得10
刚刚
满意谷波发布了新的文献求助10
1秒前
抱住仙人球应助豆子采纳,获得10
2秒前
2秒前
熊有鹏发布了新的文献求助10
4秒前
烟花应助义气平蓝采纳,获得10
6秒前
6秒前
Moira完成签到,获得积分10
7秒前
闪闪朝雪完成签到,获得积分10
7秒前
tjfwg完成签到,获得积分10
7秒前
stray发布了新的文献求助10
9秒前
10秒前
周雨婷发布了新的文献求助20
10秒前
11秒前
12秒前
善学以致用应助科研民工采纳,获得10
12秒前
12秒前
勤劳紫青发布了新的文献求助10
14秒前
天朗完成签到,获得积分10
15秒前
留胡子的问芙完成签到,获得积分10
16秒前
熊有鹏完成签到,获得积分20
17秒前
17秒前
整齐芷文发布了新的文献求助10
18秒前
23秒前
小糯米发布了新的文献求助10
24秒前
24秒前
隐形曼青应助stella采纳,获得10
25秒前
rosalieshi应助JUGG采纳,获得30
26秒前
lzb完成签到,获得积分10
29秒前
31秒前
啊汪~发布了新的文献求助10
31秒前
36秒前
khaosyi完成签到 ,获得积分10
37秒前
徐徐发布了新的文献求助10
38秒前
大个应助zz采纳,获得10
38秒前
strangeliu完成签到,获得积分10
39秒前
123发布了新的文献求助10
41秒前
41秒前
冷傲曼荷应助徐徐采纳,获得10
45秒前
Jasper应助徐徐采纳,获得10
45秒前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3050967
求助须知:如何正确求助?哪些是违规求助? 2708304
关于积分的说明 7412124
捐赠科研通 2352413
什么是DOI,文献DOI怎么找? 1245174
科研通“疑难数据库(出版商)”最低求助积分说明 605463
版权声明 595796